FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo

(Reuters) -Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss medicines, in return for Medicare coverage of their products, Endpoints News reported on Tuesday.

Under the deal, the companies would offer the lowest dose of their respective obesity drugs at $149 per month, the report said, citing sources familiar with the matter. The agreement can be announced this week, it added.

In return, the drugs would gain coverage under Medicare, a federal health insurance program in the U.S. for people aged 65 and older, which would open up a huge new set of reimbursement, according to the report.

Lilly and Novo did not immediately respond to Reuters requests for comment.

(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)